• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Greenbrook TMS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    2/26/24 1:36:08 PM ET
    $GBNH
    Misc Health and Biotechnology Services
    Health Care
    Get the next $GBNH alert in real time by email
    false 0001735948 A6 0001735948 2024-02-23 2024-02-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 23, 2024

     

     

     

    GREENBROOK TMS INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Ontario   001-40199   98-1512724

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File No.)

     

    (IRS Employee

    Identification No.)

     

    890 Yonge Street, 7th Floor

    Toronto, Ontario Canada

    M4W 3P4

    (Address of Principal Executive Offices)

     

    (866) 928-6076

    (Registrant’s telephone number, including area code)

     

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class  

    Trading

    Symbol(s)

     

    Name of Each Exchange

    on Which Registered

    Common Shares, without par value   GBNH   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On February 21, 2024, Greenbrook TMS Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain purchasers for the purchase and sale of 6,000,000 shares of the Company’s common shares (“Common Shares”) pursuant to a registered direct offering. The Common Shares were priced at US$0.20 per Common Share (the “Purchase Price”) for expected gross proceeds of approximately US$1.2 million.

     

    On February 23, 2024, the Company amended and restated the Securities Purchase Agreement (the “Amended and Restated Securities Purchase Agreement”) with the same purchasers, to reduce the offering size after receiving notice of its delisting from the Nasdaq Capital Market (“Nasdaq”). The Amended and Restated Securities Purchase Agreement provides for the purchase and sale of 2,828,249 Common Shares pursuant to a registered direct offering (the “Offering”). The Common Shares were sold at the same Purchase Price as originally contemplated for gross proceeds of approximately US$565,649, before deducting legal fees and other Offering expenses payable by the Company. The Offering was made pursuant to a prospectus supplement, dated February 23, 2024, to the base prospectus in the Company’s shelf registration statement on Form F-3 (File No. 333-264067), which was filed with the Securities and Exchange Commission (the “Commission”) on April 1, 2022, and amended on April 12, 2022, by the Company and declared effective by the Commission on April 15, 2022.

     

    A.G.P./Alliance Global Partners acted as financial advisor in connection with the Offering.

     

    On February 26, 2023, the Company completed the Offering. The net proceeds to the Company after deducting legal fees and other Offering expenses were approximately $340,650. The net proceeds from the Offering are intended to be used for general working capital.

     

    The representations, warranties and covenants contained in each Amended and Restated Securities Purchase Agreement were made solely for the benefit of the parties to the Amended and Restated Securities Purchase Agreement. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Amended and Restated Securities Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by shareholders of, or other investors in, the Company. Accordingly, a form of the Amended and Restated Securities Purchase Agreement is filed with this report only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Shareholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Amended and Restated Securities Purchase Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.

     

    In addition, in connection with the Offering, the directors and executive officers of the Company entered into lock-up agreements, which each provide for a 90-day lockup period commencing on February 23, 2024, subject to customary exceptions (the “Lock-Up Agreements”).

     

    The foregoing descriptions of the Amended and Restated Securities Purchase Agreement and the Lock-Up Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of the Amended and Restated Securities Purchase Agreement and the form of Lock-Up Agreement, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

     

    Item 8.01. Other Events. 

     

    In light of the Company’s forthcoming delisting from Nasdaq, the Company included within the prospectus supplement filed with the Commission on February 26, 2024 in connection with the Offering, updated tax disclosure for shareholders under the heading “SUPPLEMENTAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS”. 

     

     

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit   Title
         
    5.1   Opinion of Torys LLP, dated February 26, 2024
         
    10.1   Amended and Restated Securities Purchase Agreement, dated February 23, 2024, among Greenbrook TMS Inc. and certain investors
         
    10.2   Form of Lock-Up Agreement (included in Exhibit 10.1)
         
    23.1   Consent of Torys LLP (contained in Exhibit 5.1 above)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: February 26, 2024

     

      GREENBROOK TMS INC.
         
      By: /s/ Bill Leonard
      Name: Bill Leonard
      Title: President and Chief Executive Officer

     

     

     

    Get the next $GBNH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GBNH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GBNH
    SEC Filings

    See more
    • Greenbrook TMS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Greenbrook TMS Inc. (0001735948) (Filer)

      3/15/24 3:46:21 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • Greenbrook TMS Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Greenbrook TMS Inc. (0001735948) (Filer)

      3/8/24 3:19:54 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • Greenbrook TMS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Greenbrook TMS Inc. (0001735948) (Filer)

      3/1/24 4:58:50 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care

    $GBNH
    Financials

    Live finance-specific insights

    See more

    $GBNH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GREENBROOK TMS ANNOUNCES DELISTING FROM NASDAQ

      TORONTO, Feb. 23, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced receipt of the final delisting notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") due to the continued failure to satisfy either the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) or the minimum stockholders' equity requirements in Nasdaq Listing Rule 5550(b). Nasdaq has notified the Company that trading of its common shares (the "Common Shares") will be suspended as of the open of trading on February 26, 2024. After careful consideration, the Company determined that it was in the overall best interests

      2/23/24 9:00:00 AM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • GREENBROOK TMS RAISES US$2.5 MILLION IN DEBT FINANCING

      TORONTO, Feb. 15, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced that it has entered into the twenty-fifth amendment (the "Amendment") to the Company's credit facility (the "Credit Facility") with affiliates of Madryn Asset Management, LP ("Madryn"). As part of the Amendment, the Company secured an additional US$2,538,071 in senior secured term loans from Madryn under the Credit Facility (the "New Loan"). After giving effect to the New Loan, the Company has an aggregate amount of approximately US$87 million outstanding under the Credit Facility. The proceeds of the New Loan are expected to be used by the Company for general corporate an

      2/15/24 5:21:00 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • GREENBROOK TMS RAISES US$1.5 MILLION IN DEBT FINANCING

      TORONTO, Feb. 6, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced that it has entered into the twenty-fourth amendment (the "Amendment") to the Company's credit facility (the "Credit Facility") with affiliates of Madryn Asset Management, LP ("Madryn"). As part of the Amendment, the Company secured an additional US$1,522,843 in senior secured term loans from Madryn under the Credit Facility (the "New Loan"). After giving effect to the New Loan, the Company has an aggregate amount of approximately US$85 million outstanding under the Credit Facility. The proceeds of the New Loan are expected to be used by the Company for general corporate an

      2/6/24 5:15:00 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • Greybrook Announces Passing of Founder Elias Vamvakas

      TORONTO, July 11, 2024 /CNW/ - It is with heavy hearts that the Executive Team at Greybrook announces the passing of our cherished founder, Elias Vamvakas, today, after a courageous battle with pancreatic cancer. Elias was 65 years old. Elias Vamvakas was a visionary leader whose entrepreneurial spirit and dedication laid the foundation for Greybrook, a distinguished Canadian private equity firm with investments in real estate and health care. Born in 1958 in Athens, Greece, Elias immigrated to Canada in 1966. His journey from an immigrant to a celebrated business leader was a

      7/11/24 1:55:00 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • GREENBROOK TMS ANNOUNCES DELISTING FROM NASDAQ

      TORONTO, Feb. 23, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced receipt of the final delisting notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") due to the continued failure to satisfy either the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) or the minimum stockholders' equity requirements in Nasdaq Listing Rule 5550(b). Nasdaq has notified the Company that trading of its common shares (the "Common Shares") will be suspended as of the open of trading on February 26, 2024. After careful consideration, the Company determined that it was in the overall best interests

      2/23/24 9:00:00 AM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • Greenbrook Announces $1.2 Million Registered Direct Offering

      TORONTO, Feb. 22, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company"), today announced that it has entered into securities purchase agreements with  institutional investors for the purchase and sale of 6,000,000 common shares at a purchase price of $0.20 per share pursuant to a registered direct offering, resulting in gross proceeds of approximately $1.2 million before deducting placement agent commissions and other estimated offering expenses. The closing of the offering is expected to occur on or about February 26, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds for working capital as well as

      2/22/24 8:00:00 AM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care

    $GBNH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Crish Andrew

      3 - Greenbrook TMS Inc. (0001735948) (Issuer)

      3/8/24 4:51:46 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 3 filed by new insider Elstad Juliana

      3 - Greenbrook TMS Inc. (0001735948) (Issuer)

      2/2/24 4:31:30 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • New insider Madryn Asset Management, Lp claimed ownership of 6,363,636 shares (SEC Form 3)

      3 - Greenbrook TMS Inc. (0001735948) (Issuer)

      1/11/24 9:45:02 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care

    $GBNH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Greenbrook TMS Inc. (Amendment)

      SC 13D/A - Greenbrook TMS Inc. (0001735948) (Subject)

      2/28/24 5:22:33 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Greenbrook TMS Inc. (Amendment)

      SC 13D/A - Greenbrook TMS Inc. (0001735948) (Subject)

      2/28/24 3:26:24 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Greenbrook TMS Inc. (Amendment)

      SC 13D/A - Greenbrook TMS Inc. (0001735948) (Subject)

      10/24/23 4:15:27 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care

    $GBNH
    Leadership Updates

    Live Leadership Updates

    See more
    • GREENBROOK APPOINTS PETER WILLETT AS CHIEF FINANCIAL OFFICER

      TORONTO, Jan. 29, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced that the Company's Board of Directors has appointed Mr. Peter Willett as the Company's full-time Chief Financial Officer, effective immediately. Mr. Willett was appointed Interim Chief Financial Officer of the Company in October 2023, prior to which he has been a key player on the Greenbrook finance team over the past six years, serving as its Senior Vice President of Finance. Peter brings over 11 years of finance experience, providing a broad base of experience and specialized knowledge about the financial and accounting matters that are unique to the mental health servic

      1/29/24 5:00:00 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • GREENBROOK TMS ANNOUNCES DIRECTOR APPOINTMENT

      TORONTO, Jan. 23, 2024 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company") today announced that it has appointed Ms. Juliana Elstad to the Company's board of directors as an independent director, effective immediately. Ms. Elstad has also been appointed to the Company's Governance and Nominating Committee. Juliana Elstad is a CEO, entrepreneur, and advisor with over 20 years of experience bringing medical innovation to patients and delivering success in small startup to multi-billion-dollar environments. She has a proven track record of creating, growing, and leading medical technology organizations with a focus on building dynamic cultures and mentoring high-po

      1/23/24 4:31:00 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care
    • GREENBROOK TMS ANNOUNCES RESULTS OF VOTING AT ANNUAL MEETING OF SHAREHOLDERS

      TORONTO, June 20, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ:GBNH) ("Greenbrook" or the "Company"), a leading provider of Transcranial Magnetic Stimulation ("TMS") therapy in the United States, announced today the results of voting at its annual meeting of shareholders held earlier today (the "Meeting"). Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual Meeting of Shareholders and Management Information Circular of Greenbrook dated May 11, 2023 (the "Circular").   The total number of common shares represented at the Meeting was 29,769,721, representing approximately 72.96% of Greenbrook's outstanding common shares entit

      6/20/23 5:00:00 PM ET
      $GBNH
      Misc Health and Biotechnology Services
      Health Care